News

As part of the collaboration deal, the companies will use ArsenalBio’s T cells screening and engineering technology for identifying the critical success circuits in T cell-based therapies. Genentech,

Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are

The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended

A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),

Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene

Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization

As part of the partnership deal, the entities will initially plan to conduct a preclinical proof-of-concept efficacy study with the new radio-conjugate targeting Netrin-1, combining Netris’ NP137 with

The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen

Yescarta is a chimeric antigen receptor (CAR) T-cell therapy that is indicated to treat diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients whose